Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026)
Talphera's (TLPH) quarterly Total Non-Current Liabilities came in at $10.5 million in Q1 2026, up 23.58% year-on-year from $8.5 million in Q1 2025, and up 2.1% quarter-over-quarter from $10.3 million in Q4 2025.
Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Talphera's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 23.58% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 23.58% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, up 12.36% from the prior year.
- Total Non-Current Liabilities improved to $10.5 million in Q1 2026 per TLPH's latest filing, from $10.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $25.6 million in Q1 2022 and bottomed at $4.5 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $9.7 million (2025), against an average of $11.8 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 81.97% in 2022 and surged 103.32% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $18.6 million in 2022, then slumped by 75.71% to $4.5 million in 2023, then jumped by 103.32% to $9.2 million in 2024, then climbed by 12.36% to $10.3 million in 2025, then advanced by 2.1% to $10.5 million in 2026.
- Per Business Quant, the three latest TLPH Total Non-Current Liabilities figures stand at $10.5 million (Q1 2026), $10.3 million (Q4 2025), and $9.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 10.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.52 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 9.71 Mn |
| Jun 30, 2025 | 9.13 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 9.17 Mn |
| Sep 30, 2024 | 9.29 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Dec 31, 2023 | 4.51 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 7.31 Mn |
| Mar 31, 2023 | 10.26 Mn |
| Dec 31, 2022 | 18.58 Mn |
| Sep 30, 2022 | 20.77 Mn |
| Jun 30, 2022 | 22.99 Mn |
| Mar 31, 2022 | 25.63 Mn |
| Dec 31, 2021 | 28.50 Mn |
| Sep 30, 2021 | 115.18 Mn |
| Jun 30, 2021 | 115.45 Mn |